Related Experiment Videos
Glycosaminoglycans in urolithiasis.
A Nesse1, G Garbossa, M C Romero
1Laboratorio de Analisis Biologicos, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Argentina.
Nephron
|January 1, 1992
Summary
Urinary glycosaminoglycan (GAG) concentrations are lower in patients who form kidney stones. This study suggests GAGs may interact with urate, potentially affecting stone formation.
Area of Science:
- Biochemistry
- Urology
- Nephrology
Background:
- Glycosaminoglycans (GAGs) are crucial components of the urinary tract.
- Previous research suggests a role for GAGs in inhibiting kidney stone formation.
- Understanding GAG levels in stone formers is important for developing preventative strategies.
Purpose of the Study:
- To investigate differences in urinary glycosaminoglycan (GAG) concentrations between stone-forming patients and healthy controls.
- To explore potential interactions between GAGs and other urinary substances like urate in the context of stone formation.
Main Methods:
- Studied 43 stone-forming patients and 37 healthy controls.
- Measured urinary concentrations of calcium, magnesium, creatinine, uric acid, and GAGs.
- Employed the Di Ferrante precipitation and Bitter and Muir reaction for GAG quantification.
Main Results:
- Stone-forming patients exhibited significantly lower urinary GAG concentrations.
- Daily urinary GAG output was also significantly reduced in patients with stones.
- Urinary GAG levels were found to be lower in stone-forming individuals compared to controls.
Conclusions:
- Decreased urinary GAG concentration and excretion are evident in stone-forming patients.
- An interaction between GAGs and urate may influence the inhibitory capacity of GAGs against stone formation.
- Further research into GAG-urate interactions could offer new insights into kidney stone prevention.